(Q30890927)

27 June 2017

title

Temozolomide in the treatment of recurrent malignant glioma (English)

1 reference

27 June 2017

0 references

Philip Theodosopoulos

2

object named as

Philip Theodosopoulos

1 reference

27 June 2017

7

Michael D Prados

1 reference

27 June 2017

Susan M Chang

1

1 reference

27 June 2017

Kathleen Lamborn

3

1 reference

27 June 2017

Mary Malec

4

1 reference

27 June 2017

Jane Rabbitt

5

1 reference

27 June 2017

Margaretta Page

6

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

100

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

page(s)

605-611

1 reference

A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Stud

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

New chemotherapy options for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Temozolomide as second-line chemotherapy for relapsed gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Intravenous BCNU and AZQ in patients with recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Intravenous carboplatin for recurrent malignant glioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11949

7 January 2021

Identifiers

DOI

10.1002/CNCR.11949

1 reference

27 June 2017

1 reference